During Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), the United States Department of Defense adopted a policy of destroying trash generated at forward operation bases through the use of open burn pits.1–3 These were literally open pits dug into the ground, into which various types of garbage were thrown, doused with jet fuel, and burned. At Joint Base Balad in Iraq, for example, it was estimated that the base generated 5 pounds of trash per person per day. With a population of about 50,000 service personnel at any given time, this amounted to 125 tons per day of trash.2 Although open burn pits have largely been replaced by controlled incinerators at most established bases, they are still sometimes used in forward areas and temporary operating areas.
Burn pits were justified as operationally necessary, but there was only limited environmental monitoring.2,4–6 Burn pits produce a number of airborne toxicants of concern, including polyaromatic hydrocarbons (PAHs), polychlorinated biphenols (PCBs), polychlorinated dibenzo-p-dioxins (PCDDs), and polychlorinated dibenzofurans (PCDFs).5,6 A pilot study of breathing zone samples from security personnel at Bagram Airfield documented the presence of 23 volatile organic compounds and PAHs, although only acrolein naphthalene exceeded military exposure guidelines, and only on some occasions.4,7 Individual exposures varied from 10- to 100-fold from day to day and among different work locations. Because of the lack of widespread exposure monitoring, exposure to burn pits poses an unknown level of risk of long-term health impacts. Although there are reports of respiratory effects, as yet, there are no clearly confirmed long-term health consequences associated with burn pit exposure8–11; thus, there is ongoing concern, and the Veterans Administration has established a Burn Pit Registry to collect self-reported exposure and health outcome records from service personnel.12,13 There remains a critical need to be able to assess personal exposures to understand the biological impacts of burn pit exposure and the potential for future health risks.
The long-term goal of our overall study was to determine whether archived serum samples from service personnel deployed to areas with open burn pits could be used to identify personal exposures and biological responses to burn pits and other environmental hazards associated with deployment to Iraq and Afghanistan during OIF and OEF3 (see the Introduction to this issue). More broadly, can postexposure serum samples be used to gauge exposures to occupational hazards retrospectively, when contemporaneous environmental and personal monitoring is inadequate. We obtained pre- and postdeployment serum samples from 200 service personnel deployed to Iraq or Afghanistan, and an equal number of control samples from service personnel who were never deployed. We performed high-dimension, high-throughput analysis including 29 cytokines and chemokines related to inflammation and cardiopulmonary risk, 177 microRNAs, and a metabolomics analysis with over 10,000 features, of which several hundred have been identified with high confidence.14–18 To date, we have demonstrated that archival serum samples contain metabolic signatures of nutritional status and PAH exposure,19 and we identified a number of microRNAs that were correlated with deployment and with serum levels of PCDDs and PCDFs.14,20 However, we did not detect a strong signature of either PAHs, PCDDs, or PCDFs in postdeployment serum; the only PCDD that had a statistically significant association between deployment and serum level was 1,2,3,4,6,7,8-heptachloro-p-dioxin.15 As lightweight PAHs are metabolized relatively quickly,21,22 and PCDDs and PCDFs accumulate in fatty tissues,23 it is likely that serum is not the best place to search for direct evidence of exposure to these compounds. However, prior exposure may result in long-term changes to the metabolome or to expression of microRNAs, cytokines or chemokines, that could be detected in serum. Here, we apply multiple statistical and “big data” approaches to tentatively identify a “signature” group of biomarkers that can classify subjects based on their exposure to burn pits during deployment.
MATERIALS AND METHODS
Serum samples and demographic data were deidentified, and the study was approved by the Institutional Review Boards of the Uniformed Services University and the University of Rochester.
The overall study population has been described in detail elsewhere.1,3,14,19 The Case group consisted of 200 service personnel who were deployed to Joint Base Balad in Iraq between 2005 and 2007 (Operation Iraqi Freedom) or Bagram Airbase in Afghanistan from 2011 to 2012 (Operation Enduring Freedom) who had been exposed to open burn pits, and for whom pre- and postdeployment serum samples were available at the Department of Defense Serum Repository (DoDSR) in sufficient quantity to complete the planned analyses. The Control group consisted of 200 personnel who were never deployed, who had consecutive serum samples available in the DoDSR, and who were matched to the Case group for time in service at the time of the first blood draw and matched for the length of time between first and second blood draw.1,3 This strategy was adopted to control for biomarker changes associated with military service but not deployment. Demographic information was drawn from the Defense Medical Surveillance System (DMSS) and linked to the serum samples by anonymized code numbers. Upon examining the demographic database, we identified some minor discrepancies, such as postdeployment blood samples recorded as being drawn before the start of deployment. Rather than assuming that the database was incorrect and impute a more logical value, we developed a strategy to exclude subjects with inconsistent dates (Case group, N = 8) (see Figure S1, Supplemental Digital Content 1, http://links.lww.com/JOM/A652). As we wanted to assess the effects of deployment-related environmental exposures on serum biomarkers, we also excluded a small number of subjects (Case group, N = 5) with deployment duration less than 150 days. As the Control group was never deployed and the dates of “pre” and “post” samples in the Control group were arbitrarily assigned, we only excluded Control subjects with duration between serum samples of less than 150 days (N = 14). The remaining population of 187 Case and 186 Control subjects is described in Table S1, Supplemental Digital Content 2, http://links.lww.com/JOM/A653. Briefly, and as previously described,1 the Control group contained more female personnel, due to DoD policies regarding deployment of female personnel who were in place during the relevant time frames. The Case group also skewed slightly higher in rank, with a higher proportion of E5 to E9 personnel. The Case group was made up of Army and Air Force personnel due to the study design,1 whereas the Control group was drawn randomly from the DMSS database. There were no significant differences in age, race, or smoking status.
The serum sample was divided into several aliquots and processed as previously reported (see Khan et al, this issue). A panel of 21 cytokines and chemokines associated with inflammation, and a panel of 8 cardiovascular disease markers, was measured by multiplex analysis (FlexMAP 3D, Luminex Corp., Austin, TX) using Milliplex MAP kits (EMD Millipore, Billerica, MA) according to the manufacturer's instructions. Serum cotinine was measured by commercial EIA (Calbiotech, Spring Valley, CA). Serum IgE was measured by commercial ELISA (Bethyl Laboratories, Montgomery, TX). Benzo(a)pyrene diol epoxide (BPDE)-protein adducts were measured by ELISA (OxiSelect™ BPDE Protein Adduct ELISA Kit, Cell Biolabs Inc., San Diego, CA).20 RNA was extracted and used to determine levels of a panel of 144 human miRNAs commonly found in serum, as reported previously.14 A panel of 59 metabolites related to nutritional status and pesticide exposure was measured by mass spectrometry and reported previously.19 Serum levels of 17 polyaromatic hydrocarbons and 25 polychlorinated dibenzo-p-dioxins and dibenzofurans were measured by us using a novel small volume extraction method, as previously described.15 The final analysis included 279 biomarkers, as listed in Table S2, Supplemental Digital Content 3, http://links.lww.com/JOM/A654. As the dioxins and furans were sparse and zero inflated, we performed principal component analysis on the dioxin and furan measurements and retained the first principal component (PC1) to use in subsequent analyses (see Khan et al, this issue). Thus, the regression and machine learning models used 236 variables.
We developed an ordinary least squares regression model for 236 biomarker values using age, sex, and tobacco use as covariates. Complete details of the regression analysis are reported in Khan et al, this issue.
Machine Learning Model for Classification
We used a supervised linear support vector machine (SVM)24 model to classify subjects as either Case (deployed) or Control (not deployed). Briefly, the SVM uses a subset of the data (a training set) to build a model that identifies which biomarker features are most useful in correctly classifying the training set as Case or Control. Then, the model is tested with a validation set to determine how accurately that classification is reproduced. In this analysis, we used 10-fold cross-validation, which generalizes the model and minimizes the chances of overfitting the data. The data set was divided into 10 subgroups, and for each run, 9 subgroups were used as the training set and the 10th was used for validation. This process was repeated 10 times, with each subsample used once as the validation set. The results of the 10 validation runs were averaged to produce a single estimate of the overall accuracy of the SVM model. To further improve the accuracy of the model and for feature selection, we used recursive feature elimination.25 The SVM was first run using all 236 biomarker features. After each run, the least-weighted biomarker was removed and the SVM rerun on the reduced data set. Each iteration was assessed by 10-fold cross-validation. The SVM was developed both with and without adjustment for age, sex, and tobacco use. Both models assigned similar weights to most features, but at each step in the RFE, the unadjusted model required fewer features to achieve the same accuracy and cross-validation, so only the SVM using the unadjusted data is reported here. Complete details of the SVM model are reported in Khan et al, this issue.
High-Resolution Mass Spectrometry and Data Preprocessing
The metabolome was processed as described in Go et al, in this issue. In brief, a 65 μL serum aliquot was added to 130 μL of acetonitrile containing a mixture of stable isotope-labeled internal standards and prepared for metabolomics analysis using our previously established method.26–28 Samples were analyzed in triplicate by liquid chromatography with Fourier transform mass spectrometry (Dionex Ultimate 3000, Q-Exactive, Thermo Fisher) with C18 chromatography/positive electrospray ionization (ESI) mode and resolution of 70,000.29 Spectral m/z features were acquired in scan range 85 to 1250 mass-to-charge ratio (m/z). Raw data files were extracted using apLCMSv6.3.330 with xMSanalyzerv2.0.7,31 followed by batch correction with ComBat.32 Uniquely detected ions consisted of m/z, retention time and ion abundance, referred to as m/z features.
Metabolic Feature Selection
Before data analysis, triplicate injections were averaged and only m/z features with at least 80% nonmissing values in either of the groups and more than 50% nonmissing values across all samples were retained. After filtering based on missing values, data were log2 transformed and quantile normalized.33
Mapping the Interactions of the Metabolome With miRNAs Using xMWAS
miRNA and HRM data from the Case sample group were integrated by using xMWAS.34 We used sparse partial least squares regression, a variable selection and dimensionality reduction method with visualization performed by the package mixOmics, to conduct pairwise correlation analysis between the miRNA (364 samples × 14 microRNAs) and the metabolome (364 samples × 3011 metabolic features) which had been quantile normalized and log-transformed). Ten samples were removed from the Case group before xMWAS analysis due to the absence of microRNA detection in either the pre- or postdeployment samples leaving a total of 364 samples in the Case group. Thresholds for determining significant associations must have met the correlation threshold criteria (|r| > 0.3)) and P < 0.05 as determined by Student t test.
Metabolic features were annotated using xMSannotator35; confidence scores for annotation by xMSannotator are derived from a multistage clustering algorithm. Identities of selected metabolites were confirmed by co-elution relative to authentic standards and ion dissociation mass spectrometry (level 1 identification by criteria of Schymanski et al36). Supplemental annotations were made based on high or medium confidence (≥2) with M+H adducts detected in the positive mode. Lower confidence annotations were made using either the KEGG (Kyoto Encyclopedia of Genes and Genomes)37 or the HMDB (Human Metabolome Database)38 at a 5 ppm tolerance.
Micro-RNAs Associated With Serum Levels of Polychlorinated Dibenzo-p-dioxins and Dibenzofurans
We first investigated whether there were associations between serum miRNAs and serum levels of polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs). miRNAs were chosen for the initial examination because they are persistent in serum and might reflect epigenetic changes in gene expression due to prior exposures, and because our earlier analysis had reported only miRNA associations.14 This analysis used both Case and Control serum values and was agnostic as to the source of the exposure; we were looking for associations between miRNA and PCDDs/PCDFs regardless of source. Using an uncorrected regression model, we identified 56 miRNAs that were significantly associated with one or more species of PCDD or PCDF.14 Here, we repeated the analysis using our new regression model that is corrected for age, sex, and smoking status. We identified 50 miRNAs with statistically significant associations serum levels of PCDDs and PCDFs, of which 39 miRNAs were in common between both models (Figure 1A and Tables S3, http://links.lww.com/JOM/A655 and S4, http://links.lww.com/JOM/A656, Supplemental Digital Content).
We next investigated associations of all biomarkers with PCDDs and PCDFs and with benzo[a]pyrene diol epoxide (BDPE)-protein adducts. Benzo[a]pyrene is a polycyclic aromatic hydrocarbon (PAH) that is more likely associated with transportation sources (aerodrome, motor pool) and diesel electric generators than with burn pits,6 but its metabolite BDPE is highly reactive and a potent mutagen, and serum levels of BDPE-protein adducts reflect prior exposure to PAHs.39,40 We reasoned that biomarkers common to serum levels of PCDDs, PCDFs, and BDPE-protein adducts would likely be important indicators of past exposure to airborne hazards from combustion sources such as found at military bases with transportation hubs and burn pits. (Here, we are using total biomarkers including miRNA, cytokines, chemokines, and metabolites, so the number of associated biomarkers is higher than in the previous analysis of miRNA only.) Eighty-four biomarkers had significant associations with PCDDs and PCDFs, whereas 51 biomarkers had significant associations with BDPE-protein adducts (Fig. 1B and Table S5, Supplemental Digital Content, http://links.lww.com/JOM/A657). Of these, 34 were common to both (Table 1). Of particular interest are oxoproline, two members of the tryptophan pathway, kyneurinine and indoleacrylic acid, miR-144-3p, and two members of the let-7 family of miRNAs. These will be discussed in more detail below.
Biomarkers Associated With Deployment to Iraq or Afghanistan
We used the regression model corrected for age, sex, and smoking status, to identify biomarkers that were significantly associated with Case Post-Deployment, compared with Case Pre-Deployment, Control Pre-Deployment, and Control Post-Deployment (Table 2). 28 biomarkers were significantly associated with deployment, including biomarkers previously shown to be associated with PCDDs, PCDFs and BPDE-adducts, including oxoproline, indoleacrylic acid, miR-144-3p, and the let-7 family. Seven additional biomarkers that were significant between Case Post-Deployment and Case Pre-Deployment were also significant between Control Pre-deployment and Control Post-deployment, suggesting that they are likely related to age or time in service rather than deployment status.
We also used the SVM model to identify features that accurately classified Case (deployed) and Control subjects. The first run, using all 236 biomarkers, was 92% accurate but with only 66% cross-validation accuracy. To improve cross-validation accuracy, we performed recursive feature elimination. At the early stages, RFE can significantly improve validation accuracy as it removes the least-weighted classifiers, which may include biomarkers that are unrelated to deployment and constitute noise rather than signal. The feature set with the best combination of training accuracy and cross-validation accuracy contained 70 features, and achieved 86.3% training accuracy and 83.5% cross-validation accuracy (Table S6, Supplemental Digital Content, http://links.lww.com/JOM/A658). To arrive at a feature set of more manageable size, we arbitrarily selected the smallest data set that achieved both more than 80% training and cross-validation accuracy. This set contained 37 members, as shown in Figure 2, and had 82.0% training accuracy and 80.3% cross-validation accuracy. Features are ranked by weight assigned by the SVM model. The highest weighted classifier was oxoproline; miR-144-3p, kynurenine, and indoleacrylic acid were also present as before. Several markers of inflammation and cardiovascular effect were also found, including IL-6, IL-8, serum amyloid A, and α2-macroglobulin.
Finally, we compared the results of the regression model with the SVM model (Fig. 3). Although the results do not overlap completely, 11 features were common to both models, suggesting that they are strongly associated with deployment and represent biological changes that occurred as a result of deployment. That the two feature sets do not completely overlap is not surprising as the two methods ask different questions. The regression model asks which features are significantly different between groups on an individual basis; the SVM asks, when considering all the features together, which are most useful in correctly categorizing the subjects. This is discussed further in Kahn et al, this issue.
Which Biomarkers Are Associated With Both Deployment and Airborne Pollution?
The original goal of the overall study was to identify biomarkers that are associated with burn pit exposure during deployment; here, we have so far identified biomarkers associated with deployment (Fig. 3), and with certain chemicals (PCDDs and PCDFs) produced by burn pits (Table 1). We compared the lists of significant associations with identify biomarkers present in both groups. 26 biomarkers were commonly associated with both deployment and serum levels of PCDDs, PCDFs, or BDPE-protein adducts (Fig. 4). These included a number of metabolites including choline and acetyl phosphate; markers of cardiovascular risk including fetuin A and serum amyloid A; and a number of microRNAs previously reported to be involved in inflammation or biological responses to pollutant exposure.
Association of the Exposome With microRNAs Related to Deployment
Another technique to identify biomarkers common to deployment and exposure to deployment-related hazards is to use metabolome-wide association studies (MWAS). We used high performance LC–MS–MS to determine over 3000 metabolic features in the Case deployment serum samples (see Go et al, in this issue). These features include both endogenous metabolites and metabolites that originate from diet, lifestyle, environment, and behavior, or from metabolic products from those external stressors known as the exposome.41,42 Here, we investigated whether there were significant associations between a panel of 14 miRNAs that classify deployment (from Fig. 3) and the exposome in the Case group using multi-omic integration. As shown in Figure 5, xMWAS analysis identified three communities of metabolites that had statistically significant associations with six miRNAs associated with deployment. The largest community (community 2) shows positive associations between miR-103a-3p and multiple features of the exposome including 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), Tetrachloro-biphenyldiol (a polychlorinated biphenyl or PCB), and iodofenphos, an organophosphate pesticide. This community also contains sphinganine and phosphatidyl cholines, which are known to be dysregulated in inflammation.43–45 Community 1 includes metabolites from community 2 which are positively associated with miR-103 but negatively associated with miR-342-3p, including tetrachloro-biphenyldiol and prometon, an herbicide used by the DoD. Community 3 consists of a number of metabolites that are also positively associated with miR-103a, but negatively associated with miR-92a, miR-93a, miR-320, and let-7d. This shows that these miRNAs and metabolites interact in a coordinated network in which metabolic changes are associated with elevated levels of some miRNAs and depressed levels of others in individuals that were deployed. For a complete list of annotated metabolites, see Table S7, Supplemental Digital Content, http://links.lww.com/JOM/A659.
The critical problem in understanding the risks of burn pit exposure is a lack of personalized quantitative data on individual exposures. We may assume that personnel stationed close to the burn pits had higher exposure than other base personnel, but even this is affected by wind direction, location of duty stations, barracks, and other factors that are poorly documented. The Department of Defense is developing an Individual Longitudinal Exposure Record (ILER) that will keep track of an individual's potential exposures and be accessible to future health care providers, but this has not been implemented yet. For now, the only exposure records available for warfighters during OIF and OEF are self-reported, either on form DD2966 “Post deployment health assessment,” form DD2900 “Post-deployment health reassessment” or reported to the VA Airborne Hazards and Open Burn Pit Registry,12,13 and even these records are not quantitative and do not identify the specific exposure. This study was undertaken to investigate whether burn pit exposure leaves a biological signal that can be identified in archived serum samples. We were unable to identify a statistically significant increase in any hydrocarbon pollutants associated with burn pit exposure other than 1,2,3,4,6,7,8-heptachloro-p-dioxin in postdeployment serum samples.15 However, we reasoned that such exposures might result in other biological changes that would have a serum signal, including changes in metabolism, inflammatory signaling pathways, and microRNA expression. We report here the identification of a group of biomarkers that were significantly associated with exposure to chemicals produced by burn pits and motor transportation (Fig. 1) and another group of biomarkers that could be used to classify individuals as either deployed or not deployed (Figs. 2 and 3). These two groups of biomarkers had 26 elements in common (Fig. 4) which we suggest may represent a biological signal of exposure to burn pits during deployment. Given that specific environmental toxicants may be short-lived, or difficult to detect in serum, but nevertheless may have long-term health consequences, the potential to use miRNAs as a readily detectable source of information about past exposures is a significant advance toward the goal of retrospective identification of the health impacts of deployment to areas with environmental hazards.
The best way to confirm that these biomarkers are responsive to chemicals associated with burn pits would be to perform a second study on an independent cohort of service personnel deployed to a different environment where burns pits are in use. Unfortunately, we are constrained by sample availability and the movement of the DoD toward the use of regulated incinerators. Therefore, we have used two different alternative approaches to confirm our findings. For one, we have exposed primary human lung cells to selected PAHs and PCDDs, and confirmed that the exposures alter their expression of key miRNAs identified in this study (see Woeller et al, in this issue). We also took a bioinformatics approach in which we looked for correlations between key miRNAs and our metabolomic results, to see if we could confirm that these miRNAs were associated with environmental exposures (Fig. 5). Six miRNAs that were associated with PCDDs, PCDFs, or PAHs, and deployment, formed three communities with a large group of metabolic features. Some of these features included important dioxins and PCBs, a pesticide, an herbicide, and sphingolipids, and phosphatidyl cholines, which are known to be dysregulated in inflammation.45 Go et al (this issue) report that a similar MWAS analysis identified associations between sphingolipids and tetrachloro-biphenyldiol and serum levels of the PAHs benzo (ghi)perylene and fluoranthene. These results are supportive of our hypothesis that exposure to PAHs, PCDDs, and PCDFs causes metabolic changes associated with miRNAs, and that these miRNAs could be signals of exposure to environmental hazards including airborne pollutants produced from burn pits.
The importance of these biomarkers for understanding potential long-term health risks of burn pit exposure needs further exploration. MicroRNAs are small RNA hairpin structures that act to repress their target genes. miRNAs frequently target multiple genes in the same metabolic pathway, resulting in coordinated changes in gene expression along that pathway.46,47 Expression of miRNAs can be controlled epigenetically, meaning that alterations in miRNA expression can persist even after the original insult is no longer detectable,48 and recent research has identified specific miRNAs that are associated with specific diseases.49–51 The biologic targets of the miRNAs identified in Figures 4 and 5 include genes involved in lipid and glucose metabolism, diabetes and fatty liver disease, and cell proliferation and cancer.52–59 Conversely, miRNAs Let-7d and miR342 are considered tumor suppressors, so that loss of expression could contribute to increased cancer risk.60–62 miR-320b showed a high correlation with PAH levels in coke oven workers in China,63 and was associated with increased cardiovascular risk, further supporting an association between miR320b and burn pit exposure. Finally, miR-103 was elevated in lung transplant patients with bronchiolitis obliterans syndrome, suggesting it could be an important biomarker for lung disease.64
In addition to miRNAs, altered metabolism of several amino acids is also common to deployment and exposure to hydrocarbon air pollution. The importance of most of these is difficult to understand without further study. However, we are particularly intrigued by the presence of indoleacrylic acid, kynurenine, and tryptophan among the list of biomarkers associated with both deployment and air pollution. The tryptophan pathway is closely tied to the aryl hydrocarbon receptor (AhR). Although the AhR is best known as the key transcription factor responsible for sensing PAH exposure and upregulating phase I and phase II detoxifying pathways,65 it also plays important roles in downregulating immune responses to maintain homeostasis, and in cancer suppression. Kynurenine is an endogenous ligand for the AhR, and is produced from tryptophan by the indoleamine 2,3-dioxygenase (IDO) family of enzymes, whereas IDO activity is regulated by AhR signaling.66–68 Indoleacrylic acid is an endogenous inhibitor of tryptophan synthetase.69 Activation of AhR signaling due to exposure to hydrocarbon air pollution would be predicted to upregulate production of kynurenine to maintain immune homeostasis; loss of this response could contribute to the development of an inflammatory response, autoimmunity, or cancer.70,71 Thus, identification of kynurenine as an important classifier of both burn pit exposure and deployment is highly suggestive and worthy of further study.
An important limitation of this study is that it was performed on a small number of individuals (200) who were apparently healthy and did not show increased risk of any disease after deployment.1 Future studies might benefit from starting with a larger group of deployed personnel and then identifying subgroups for analysis who present with possible deployment-related illness. The availability and long-term stability of serum collected in the DoD Serum Repository makes it feasible to identify personnel with specific diseases decades after deployment, and compare their immediate post-deployment sera with post-deployment sera from personnel with similar deployment records who did not get sick. Future studies might also benefit by integrating the ILER database, such as by identifying a large group of deployed personnel and then stratifying their exposures using the ILER. Focusing on (for example) the top and bottom deciles (most and least exposed) may maximize the signal-to-noise ratio.
Another issue regarding biomarkers of deployment (Figs. 2 and 3) is that deployed personnel are subject environmental factors beyond combustion sources like burn pits and motor transportation, including insects, sandstorms, change in diet and sleeping habits, combat stress, and many others. Out of 277 biomarkers studied, we identified 54 that were significantly associated with deployment, only 26 of which were also associated with exposure to combustion products like burn pits. Future study is needed to identify whether these other biomarkers are biologically important and what their triggers are. This could be addressed in part, by studying an independent cohort of personnel deployed to a different environment.
It is also important to recognize that we have not established a cause and effect relationship between miRNAs and the metabolome. It could be that exposure to air pollution associated with burn pits causes metabolic changes which then result in changes in miRNA expression; or that these chemicals cause direct changes in gene expression including miRNAs that are translated into alterations of metabolic pathways. Because PAHs, dioxins and furans were below the limit of detection in more than 50% of postdeployment serum samples, but the miRNAs were detected in 70% to 99% of samples, we think this supports the idea that miRNAs are suitable surrogate reporter of environmental exposures, especially when the exposures are difficult to detect in the small amounts of serum available in this study.
Finally, although we have taken substantial steps to show that biomarkers associated with deployment to burn pit areas in the machine learning and statistical models are also associated with PAHs and PCDDs using independent data sets and experiments, we are aware that association does not prove causation, and further work in this area is needed.
Taken together with our previous studies (14–16,20 and this volume) we conclude that archived serum samples from the DoD Serum Repository represent a viable source of material to study the health effects of deployment; that deployment leaves a biological signature in the serum; and that some features of the deployment signature are also consistent with exposure to hydrocarbon air pollution produced by open burn pits and transportation activities. This supports the concept that routine post-deployment serum samples can be used to obtain (indirect and retrospective) information about a warfighter's exposure to environmental hazards. These results will form the foundation for future studies of potential deployment-related illnesses.
1. Rohrbeck P, Hu Z, Mallon CT. Assessing health outcomes after environmental exposures associated with open pit burning in deployed US service members. J Occup Environ Med
2. Medicine), IIo. 2011. Long-Term Health Consequences of Exposures to Burn Pits
in Iraq and Afghanistan. The National Academies Press, Washington, DC.
3. Mallon CT, Rohrbeck MP, Haines MK, et al. Introduction to department of defense research on burn pits
, biomarkers, and health outcomes related to deployment
in Iraq and Afghanistan. J Occup Environ Med
4. Blasch KW, Kolivosky JE, Heller JM. Environmental air sampling near burn pit and incinerator operations at Bagram airfield, Afghanistan. J Occup Environ Med
5. Masiol M, Mallon CT, Haines KM Jr, Utell MJ, Hopke PK. Airborne dioxins
, furans, and polycyclic aromatic hydrocarbons exposure to military personnel in Iraq. J Occup Environ Med
6. Masiol M, Mallon CT, Haines KM Jr, Utell MJ, Hopke PK. Source apportionment of airborne dioxins
, furans, and polycyclic aromatic hydrocarbons at a United States Forward Operating Air Base During the Iraq War. J Occup Environ Med
7. Blasch K, Kolivosky J, Hill B. Occupational exposures among personnel working near combined burn pit and incinerator operations at Bagram Airfield, Afghanistan. Inhal Toxicol
8. Morris MJ, Skabelund AJ, Rawlins FA 3rd, Gallup RA, Aden JK, Holley AB. Study of Active Duty Military Personnel for Environmental Deployment
Exposures: Pre- and Post-Deployment
Spirometry (STAMPEDE II). Respir Care
9. Baird C. Deployment
exposures and long-term health risks: the shadow of war. US Army Med Dep J
10. Morris MJ, Rawlins FA, Forbes DA, Skabelund AJ, Lucero PF. Deployment
-related respiratory issues. US Army Med Dep J
11. Liu J, Lezama N, Gasper J, et al. Burn pit emissions exposure and respiratory and cardiovascular conditions among airborne hazards and open burn pit registry participants. J Occup Environ Med
12. Savitz DA, Styka AN and Butler DA, eds. Assessment of the Department of Veterans Affairs Airborne Hazards and Open Burn Pit Registry. Washington DC; National Academies Press, 2017.
13. Eschenbacher WL. Veterans administration burn pit registry. Ann Am Thorac Soc
14. Woeller CF, Thatcher TH, Van Twisk D, et al. MicroRNAs as novel biomarkers of deployment
status and exposure to polychlorinated Dibenzo-p-Dioxins
/Dibenzofurans. J Occup Environ Med
15. Xia X, Carroll-Haddad A, Brown N, Utell MJ, Mallon CT, Hopke PK. Polycyclic aromatic hydrocarbons and polychlorinated Dibenzo-p-Dioxins
/Dibenzofurans in microliter samples of human serum as exposure indicators. J Occup Environ Med
16. Walker DI, Mallon CT, Hopke PK, et al. Deployment
-associated exposure surveillance with high-resolution metabolomics. J Occup Environ Med
17. Walker DI, Pennell KD, Uppal K, et al. Pilot metabolome-wide association study of benzo(a)pyrene in serum from military personnel. J Occup Environ Med
18. Liu KH, Walker DI, Uppal K, et al. High-resolution metabolomics assessment of military personnel: evaluating analytical strategies for chemical detection. J Occup Environ Med
19. Accardi CJ, Walker DI, Uppal K, et al. High-resolution metabolomics for nutrition and health assessment of armed forces personnel. J Occup Environ Med
20. Woeller CF, Thatcher TH, Van Twisk D, et al. Detection of serum microRNAs from Department of Defense Serum Repository: correlation with cotinine, cytokine, and polycyclic aromatic hydrocarbon levels. J Occup Environ Med
21. Li Z, Romanoff L, Bartell S, et al. Excretion profiles and half-lives of ten urinary polycyclic aromatic hydrocarbon metabolites after dietary exposure. Chem Res Toxicol
22. Brzeznicki S, Jakubowski M, Czerski B. Elimination of 1-hydroxypyrene after human volunteer exposure to polycyclic aromatic hydrocarbons. Int Arch Occup Environ Health
23. Registry, AfTSaD. 1995. Public Health Statement. Polycyclic aromatic hydrocarbons (PAHs). Atlanta GA.
24. Cortes C, Vapnik V. Support-vector networks. Machine Learning
25. Guyon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. Mach Learn
26. Park YH, Lee K, Soltow QA, et al. High-performance metabolic profiling of plasma from seven mammalian species for simultaneous environmental chemical surveillance and bioeffect monitoring. Toxicology
27. Soltow QA, Strobel FH, Mansfield KG, Wachtman L, Park Y, Jones DP. High-performance metabolic profiling with dual chromatography-Fourier-transform mass spectrometry (DC-FTMS) for study of the exposome. Metabolomics
28. Go YM, Kim CW, Walker DI, et al. Disturbed flow induces systemic changes in metabolites in mouse plasma: a metabolomics study using ApoE(-)/(-) mice with partial carotid ligation. Am J Physiol Regul Integr Comp Physiol
29. Jones DP, Walker DI, Uppal K, Rohrbeck P, Mallon CT, Go YM. Metabolic pathways and networks associated with tobacco use in military personnel. J Occup Environ Med
30. Yu T, Park Y, Li S, Jones DP. Hybrid feature detection and information accumulation using high-resolution LC-MS metabolomics data. J Proteome Res
31. Uppal K, Soltow QA, Strobel FH, et al. xMSanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data. BMC Bioinformatics
32. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics
33. Patel RM, Roback JD, Uppal K, Yu T, Jones DP, Josephson CD. Metabolomics profile comparisons of irradiated and nonirradiated stored donor red blood cells. Transfusion
34. Uppal K, Ma C, Go YM, Jones DP, Wren J. xMWAS: a data-driven integration and differential network analysis tool. Bioinformatics
35. Uppal K, Walker DI, Jones DP. xMSannotator: an R package for network-based annotation of high-resolution metabolomics data. Anal Chem
36. Schymanski EL, Jeon J, Gulde R, et al. Identifying small molecules via high resolution mass spectrometry: communicating confidence. Environ Sci Technol
37. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res
38. Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res
39. Borska L, Andrys C, Krejsek J, et al. Serum level of antibody against benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in people dermally exposed to PAHs. J Immunol Res
40. Sabbioni G, Turesky RJ. Biomonitoring human albumin adducts: the past, the present, and the future. Chem Res Toxicol
41. Escher BI, Hackermuller J, Polte T, et al. From the exposome to mechanistic understanding of chemical-induced adverse effects. Environ Int
42. Niedzwiecki MM, Walker DI, Vermeulen R, Chadeau-Hyam M, Jones DP, Miller GW. The exposome: molecules to populations. Annu Rev Pharmacol Toxicol
43. Ghidoni R, Caretti A, Signorelli P. Role of sphingolipids in the pathobiology of lung inflammation. Mediators Inflamm
44. Norris GH, Blesso CN. Dietary and endogenous sphingolipid metabolism in chronic inflammation. Nutrients
2017; 9:pii: E1180.
45. Lent-Schochet D, McLaughlin M, Ramakrishnan N, Jialal I. Exploratory metabolomics of metabolic syndrome: a status report. World J Diabetes
46. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res
47. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell
48. Yao Q, Chen Y, Zhou X. The roles of microRNAs in epigenetic regulation. Curr Opin Chem Biol
49. Cogswell JP, Ward J, Taylor IA, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis
50. Wu L, Dai X, Zhan J, et al. Profiling peripheral microRNAs in obesity and type 2 diabetes mellitus. APMIS
51. Ovchinnikova ES, Schmitter D, Vegter EL, et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail
52. Jin X, Chen Y, Chen H, et al. Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res
53. Xu Q, Li Y, Shang YF, Wang HL, Yao MX. miRNA-103: molecular link between insulin resistance and nonalcoholic fatty liver disease. World J Gastroenterol
54. Zhang Y, Li T, Qiu Y, et al. Serum microRNA
panel for early diagnosis of the onset of hepatocellular carcinoma. Medicine (Baltimore)
55. Stojanovic J, Tognetto A, Tiziano DF, et al. MicroRNAs expression profiles as diagnostic biomarkers of gastric cancer: a systematic literature review. Biomarkers
56. Hansen TC, Woeller CF, Lacy SH, Koltz PF, Langstein HN, Phipps RP. Thy1 (CD90) expression is elevated in radiation-induced periprosthetic capsular contracture: implication for novel therapeutics. Plast Reconstr Surg
57. Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature
58. Li M, Liu Z, Zhang Z, Liu G, Sun S, Sun C. miR-103 promotes 3T3-L1 cell adipogenesis through AKT/mTOR signal pathway with its target being MEF2D. Biol Chem
59. Holik AK, Lieder B, Kretschy N, Somoza MM, Held S, Somoza V. N()-Carboxymethyllysine increases the expression of miR-103/143 and enhances lipid accumulation in 3T3-L1 cells. J Cell Biochem
60. Huang Y, Chi C. Glioma cell proliferation is inhibited by miR-342-3p, miR-377/E2F1 signaling pathway. Neoplasma
61. Li Y, VandenBoom TG 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res
62. Kolenda T, Przybyla W, Teresiak A, Mackiewicz A, Lamperska KM. The mystery of let-7d—a small RNA with great power. Contemp Oncol (Pozn)
63. Huang S, Deng Q, Feng J, et al. Polycyclic aromatic hydrocarbons-associated microRNAs and heart rate variability in coke oven workers. J Occup Environ Med
64. Budding K, Rossato M, van de Graaf EA, Kwakkel-van Erp JM, Radstake T, Otten HG. Serum miRNAs as potential biomarkers for the bronchiolitis obliterans syndrome after lung transplantation. Transpl Immunol
65. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem
66. Rothhammer V, Quintana FJ. The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat Rev Immunol
67. Bilir C, Sarisozen C. Indoleamine 2,3-dioxygenase (IDO): only an enzyme or a checkpoint controller? J Oncological Sci
68. Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J
69. Matchett WH. Inhibition of tryptophan synthetase by indoleacrylic acid. J Bacteriol
70. Moon YW, Hajjar J, Hwu P, Naing A. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer
71. Nguyen NT, Nakahama T, Le DH, Van Son L, Chu HH, Kishimoto T. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol